Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma

Abstract

Our data suggest that combined preoperative CEA and CA 19-9 levels are suitable for assessing expected curability and resectability in patients with pancreatic cancer.

Esophageal Cancer Management: Preoperative CA19.9 and CEA Serum Levels May Identify Occult Advanced Adenocarcinoma

“…Moreover, both these markers were higher in patients with metastatic gastric cancer [25]. Similarly, in pancreatic cancer CA19-9 serum levels were significantly higher in patients who had R1/R2 resection or in those with unresectable disease than in those with resectable disease, [26,27]. Our data and these observation suggest that in esophageal cancer also, high levels of CEA and CA19-9 are biomarkers of advanced disease.…”

Serum CA 19-9 as a Biomarker for Pancreatic Cancer—A Comprehensive Review

“…Post-treatment CA 19-9 serum levels <61 U/ml also had a high PPV of 93% but a diminishing NPV of 28% in regards to predicting successful completion of pancreati-coduodenectomy among resectable patients [49]. Although post-treatment CA 19-9 serum levels in the above mentioned study had a high PPV in regards to likelihood of resectability following neo-adjuvant chemotherapy, the low NPV highlights the importance of re-staging radiographic evaluation as well as laparoscopy prior to surgical exploration [34,49].…”

“…Nevertheless, up to 15% of patients with pancreatic cancer are found unresectable at the time of surgery, which is attributable to occult vascular invasion, presence of undetected metastasis or positive peritoneal lavage cytology [25]. Whether preoperative CA 19-9 serum levels can serve as a surrogate marker for tumor resectability has been extensively evaluated [22,25,26,[29][30][31][32][33][34][35][36] (Table 3). Schleiman et al evaluated preoperative CA 19-9 serum levels in 89 pancreatic cancer patients prior to surgical exploration and noted that mean CA 19-9 serum levels were significantly lower in resectable tumors compared to those with locally advanced tumors (63 vs. 592 U/ml, p<0.003) or with metastatic disease (63 vs. 1,387 U/ml, p<0.001) [32] (Table 3).…”

Pancreatic Cancer with Normal CA 19-9 and Lewis Antigen Negative—Case Report

“…Furthermore, CA 19-9 has a questionable role as chemotherapy response predictive factor, but a well establish role in predict resecability [12][13][14][15][16][17], prognosis and in follow-up of these patients [7][8][9][10][11][12].…”